ARIEL2 Clinical Trial
An Investigational Drug for Advanced Ovarian Cancer
ARIEL2 (NCT# 01891344) is a Phase 2 trial for women with relapsed, high-grade serous or endometrioid ovarian cancer. ARIEL2 is designed to evaluate rucaparib for the treatment of women with relapsed, high-grade serous or endometrioid ovarian, fallopian tube or primary peritoneal cancer. ARIEL2 aims to evaluate biomarkers to predict how a woman with advanced ovarian cancer may respond to treatment, as well as the overall efficacy and safety of rucaparib in advanced ovarian cancer. These biomarkers will be incorporated into an investigational test that will be used in the ARIEL2 and ARIEL3 study.
Participating in the ARIEL2 Clinical Trial
The ARIEL2 trial aims to determine whether an investigational drug, rucaparib, is effective and safe. Rucaparib is currently only available in clinical trials. Participants who have received at least three lines of prior chemotherapy will be tested for the presence of biomarkers, including BRCA1 and BRCA2 mutations as well as other markers that may be important. In this study, all participants will receive rucaparib until their disease worsens or they withdraw from the study.
The primary goal of the study is to identify the women with ovarian, fallopian tube or primary peritoneal cancer who are most likely to respond to rucaparib. Rucaparib is an investigational drug, which means it has not been approved by the FDA for use as a prescription medicine.
If you qualify for the ARIEL2 trial, you will receive the following as part of the study: study-related physical exams, lab test results including BRCA and other biomarker tests, and the study drug (rucaparib).